HEPARIN SODIUM 20000UNITS IN 5% DEXTROSE INJ SOLUTION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

DEXTROSE; HEPARIN SODIUM

Доступна с:

B. BRAUN MEDICAL INC

код АТС:

B01AB51

ИНН (Международная Имя):

HEPARIN, COMBINATIONS

дозировка:

5G; 4000UNIT

Фармацевтическая форма:

SOLUTION

состав:

DEXTROSE 5G; HEPARIN SODIUM 4000UNIT

Администрация маршрут:

INTRAVENOUS

Штук в упаковке:

500 ML

Тип рецепта:

Ethical

Терапевтические области:

HEPARINS

Обзор продуктов:

Active ingredient group (AIG) number: 0220064001; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

1998-06-16

Характеристики продукта

1
Y36-002-809 LD-278-2
PRODUCT MONOGRAPH
CIV
HEPARIN SODIUM IN 5% DEXTROSE INJECTION
Solution, Heparin Sodium 20,000 units in 5% Dextrose Injection
Solution, Heparin Sodium 25,000 units in 5% Dextrose Injection
Prescribed
Therapeutic Classification: Heparin (B01AB01)
Manufactured by:
B. BRAUN MEDICAL INC.
2525 McGaw Avenue Date of Revision:
Irvine, CA 92614-5895 USA July 17, 2012
www.bbraunusa.com
Distributed by:
B. Braun Medical Inc.
2000 Ellesmere Road, Unit 16
Scarborough, Ontario M1H 2W4
Control #: 161380
Date of approval: May 28, 2013
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT
INFORMATION.........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
...................................................................................................7
DRUG
INTERACTIONS....................................................................................................9
DOSAGE AND
ADMINISTRATION...............................................................................11
OVERDOSAGE
................................................................................................................13
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................15
PART II: SCIENTIFIC INFORMATION
...............................................................................16
PHARMACEUTICAL
INFORMATION..................................